Kymera IPO Presentation Deck

STAT3 Degrader Clinical Development Plan in Liquid and Solid Tumors KYMERA IND Target Date H2 2021 H2 2022 Phase 1 Liquid and Solid Tumors • Multi-center dose escalation study -R/R B patients Milestones IND and Study Start Clinical POC • Safety, tolerability, PK and PD (POB) and preliminary clinical activity • P1b Expansion cohort in liquid and solid tumors separately • Option to amend protocol to explore select combinations . Clinical and biomarker endpoints POC

View entire presentation